Department of Neuroscience and Behavior Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.
Department of Neuroscience and Behavior Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.
Int Rev Neurobiol. 2024;177:205-234. doi: 10.1016/bs.irn.2024.05.003. Epub 2024 Jul 2.
Anxiety disorders are highly prevalent psychiatric disorders, characterized by a chronic course and often accompanied by comorbid symptoms that impair functionality and decrease quality of life. Despite advances in basic and clinical research in our understanding of these disorders, currently available pharmacological options are associated with limited clinical benefits and side effects that frequently lead to treatment discontinuation. Importantly, a significant number of patients do not achieve remission and live with lifelong residual symptoms that limit daily functioning. Since the 1970s, basic and clinical research on cannabidiol (CBD), a non-psychotomimetic compound found in the Cannabis sativa plant, has indicated relevant anxiolytic effects, garnering attention for its therapeutic potential as an option in anxiety disorder treatment. This chapter aims to review the history of these studies on the anxiolytic effects of CBD within the current understanding of anxiety disorders. It highlights the most compelling current evidence supporting its anxiolytic effects and explores future perspectives for its clinical use in anxiety disorders.
焦虑症是一种高发的精神疾病，其特征为慢性病程，常伴有功能损害和生活质量下降的共病症状。尽管我们在这些疾病的基础和临床研究方面取得了进展，但目前可用的药物选择与有限的临床益处相关，且常伴有副作用，导致治疗中断。重要的是，相当数量的患者无法达到缓解，并且终生残留的症状限制了日常功能。自 20 世纪 70 年代以来，对大麻素（CBD）的基础和临床研究表明 CBD 具有相关的抗焦虑作用，这种非致幻化合物存在于大麻植物中，引起了人们对其作为焦虑症治疗选择的治疗潜力的关注。本章旨在回顾当前对 CBD 的抗焦虑作用的研究历史，以及在当前对焦虑症的理解范围内。它突出了最引人注目的当前证据，支持其抗焦虑作用，并探讨了其在焦虑症中的临床应用的未来前景。
